Non-Hodgkin Lymphoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Non-Hodgkin Lymphoma – Pipeline Review, H2 2017’, provides an overview of the Non-Hodgkin Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma

The report reviews pipeline therapeutics for Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects

The report assesses Non-Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

4SC AG

AB Science SA

AbbVie Inc

ACEA Biosciences Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics Sarl

Affimed GmbH

Affitech A/S

Aileron Therapeutics Inc

Allinky Biopharma

Altor BioScience Corp

Amgen Inc

Angimmune LLC

arGEN-X BV

Ariad Pharmaceuticals Inc

Arno Therapeutics Inc

ArQule Inc

Arrien Pharmaceuticals LLC

Arven Ilac

Asana BioSciences LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Autolus Ltd

Bantam Pharmaceutical LLC

Bayer AG

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Bio-Path Holdings Inc

BioAtla LLC

Biocon Ltd

BioInvent International AB

BioLineRx Ltd

Bionovis SA

BioSight Ltd

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Cascadian Therapeutics Inc

Celgene Corp

Cell Medica Ltd

Cell Source Inc

Cell>Point LLC

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Cellectis SA

Celleron Therapeutics Ltd

Celltrion Inc

Cellular Biomedicine Group Inc

Celon Pharma SA

Centrose LLC

Cerenis Therapeutics Holding SA

CerRx Inc

Chipscreen Biosciences Ltd

Clevexel Pharma SAS

Coherus BioSciences Inc

CrystalGenomics Inc

CSPC Pharmaceutical Group Limited

CTI BioPharma Corp

Curis Inc

Cyclacel Pharmaceuticals Inc

CytomX Therapeutics Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

Denovo Biopharma LLC

Dynavax Technologies Corp

eFFECTOR Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Epizyme Inc

Erytech Pharma SA

Evotec AG

F. Hoffmann-La Roche Ltd

Forma Therapeutics Inc

Formula Pharmaceuticals Inc

Forty Seven Inc

Galderma SA

Genentech Inc

Genor BioPharma Co Ltd

Genosco Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Grupo Ferrer Internacional SA

GT Biopharma Inc

H3 Biomedicine Inc

Heidelberg Pharma GmbH

Humorigin Biotechnology Corp

Hutchison MediPharma Ltd

iDD biotech SAS

IGF Oncology LLC

Ignyta Inc

Immune Design Corp

ImmunGene Inc

ImmunoGen Inc

Immunomedics Inc

Immunovaccine Inc

Incyte Corp

Inflection Biosciences Ltd

Innate Pharma SA

Innovent Biologics Inc

Japan Tobacco Inc

JHL Biotech Inc

Johnson & Johnson

Juno Therapeutics Inc

K-Stemcell Co Ltd

Kainos Medicine Inc

Karyopharm Therapeutics Inc

Kite Pharma Inc

Klyss Biotech Inc

Komipharm International Co Ltd

Kyowa Hakko Kirin Co Ltd

Leadiant Biosciences Inc

Les Laboratoires Servier SAS

LFB SA

Loxo Oncology Inc

LSK BioPartners Inc

Mabion SA

MacroGenics Inc

Meabco AS

MedImmune LLC

Medivir AB

MEI Pharma Inc

MENTRIK Biotech LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Miltenyi Biotec GmbH

Miragen Therapeutics Inc

Mirati Therapeutics Inc

Molecular Templates Inc

Moleculin Biotech Inc

Morphogenesis Inc

MorphoSys AG

NantKwest Inc

NBE-Therapeutics AG

Neumedicines Inc

Nichi-Iko Pharmaceutical Co Ltd

Nordic Nanovector ASA

NovaLead Pharma Pvt Ltd

Novartis AG

NovImmune SA

Oncobiologics Inc

Onconova Therapeutics Inc

Oncopeptides AB

OncoSec Medical Inc

Oncovir Inc

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

Onxeo SA

Oxford BioTherapeutics Ltd

Patrys Ltd

Pfizer Inc

Pharma Mar SA

Philogen SpA

PIQUR Therapeutics AG

Plexxikon Inc

Polaris Pharmaceuticals Inc

Portola Pharmaceuticals Inc

Prescient Therapeutics Ltd

Rafael Pharmaceuticals Inc

RedHill Biopharma Ltd

Regeneron Pharmaceuticals Inc

Respiratorius AB

Rhizen Pharmaceuticals SA

Richter Gedeon Nyrt

Sandoz International GmbH

Sanofi

Sareum Holdings Plc

Seattle Genetics Inc

Selvita SA

Senhwa Biosciences Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Pharmaceutical Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Sierra Oncology Inc

Sigma-Tau SpA

Solasia Pharma KK

Soligenix Inc

Sorrento Therapeutics Inc

Spectrum Pharmaceuticals Inc

Stemline Therapeutics Inc

Sunesis Pharmaceuticals Inc

Supratek Pharma Inc

Surface Oncology Inc

Sutro Biopharma Inc

Syndax Pharmaceuticals Inc

Taiho Pharmaceutical Co Ltd

Taiwan Liposome Company Ltd

TC BioPharm Ltd

Teva Pharmaceutical Industries Ltd

TG Therapeutics Inc

TRACON Pharmaceuticals Inc

Transgene Biotek Ltd

Transgene SA

Trillium Therapeutics Inc

Trovagene Inc

TTY Biopharm Company Ltd

United BioPharma Inc

Unum Therapeutics Inc

Verastem Inc

Vivolux AB

Vyriad Inc

Xencor Inc

Xenetic Biosciences Inc

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 11

Non-Hodgkin Lymphoma - Overview 12

Non-Hodgkin Lymphoma - Therapeutics Development 13

Non-Hodgkin Lymphoma - Therapeutics Assessment 94

Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 120

Non-Hodgkin Lymphoma - Drug Profiles 233

Non-Hodgkin Lymphoma - Dormant Projects 1899

Non-Hodgkin Lymphoma - Discontinued Products 1921

Non-Hodgkin Lymphoma - Product Development Milestones 1929

Appendix 1939

List of Tables

List of Tables

Number of Products under Development for Non-Hodgkin Lymphoma, H2 2017 63

Number of Products under Development by Companies, H2 2017 65

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 66

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 67

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 68

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 69

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 70

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 71

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 72

Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 73

Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 74

Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 75

Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017 76

Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017 77

Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017 78

Number of Products under Development by Universities/Institutes, H2 2017 79

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 81

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 82

Products under Development by Companies, H2 2017 83

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 84

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 85

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 86

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 87

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 88

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 89

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 90

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 91

Products under Development by Companies, H2 2017 (Contd..9), H2 2017 92

Products under Development by Companies, H2 2017 (Contd..10), H2 2017 93

Products under Development by Companies, H2 2017 (Contd..11), H2 2017 94

Products under Development by Companies, H2 2017 (Contd..12), H2 2017 95

Products under Development by Companies, H2 2017 (Contd..13), H2 2017 96

Products under Development by Companies, H2 2017 (Contd..14), H2 2017 97

Products under Development by Companies, H2 2017 (Contd..15), H2 2017 98

Products under Development by Companies, H2 2017 (Contd..16), H2 2017 99

Products under Development by Companies, H2 2017 (Contd..17), H2 2017 100

Products under Development by Companies, H2 2017 (Contd..18), H2 2017 101

Products under Development by Companies, H2 2017 (Contd..19), H2 2017 102

Products under Development by Companies, H2 2017 (Contd..20), H2 2017 103

Products under Development by Companies, H2 2017 (Contd..21), H2 2017 104

Products under Development by Companies, H2 2017 (Contd..22), H2 2017 105

Products under Development by Companies, H2 2017 (Contd..23), H2 2017 106

Products under Development by Companies, H2 2017 (Contd..24), H2 2017 107

Products under Development by Companies, H2 2017 (Contd..25), H2 2017 108

Products under Development by Companies, H2 2017 (Contd..26), H2 2017 109

Products under Development by Companies, H2 2017 (Contd..27), H2 2017 110

Products under Development by Companies, H2 2017 (Contd..28), H2 2017 111

Products under Development by Companies, H2 2017 (Contd..29), H2 2017 112

Products under Development by Companies, H2 2017 (Contd..30), H2 2017 113

Products under Development by Companies, H2 2017 (Contd..31), H2 2017 114

Products under Development by Companies, H2 2017 (Contd..32), H2 2017 115

Products under Development by Companies, H2 2017 (Contd..33), H2 2017 116

Products under Development by Companies, H2 2017 (Contd..34), H2 2017 117

Products under Development by Companies, H2 2017 (Contd..35), H2 2017 118

Products under Development by Companies, H2 2017 (Contd..36), H2 2017 119

Products under Development by Companies, H2 2017 (Contd..37), H2 2017 120

Products under Development by Companies, H2 2017 (Contd..38), H2 2017 121

Products under Development by Companies, H2 2017 (Contd..39), H2 2017 122

Products under Development by Companies, H2 2017 (Contd..40), H2 2017 123

Products under Development by Companies, H2 2017 (Contd..41), H2 2017 124

Products under Development by Companies, H2 2017 (Contd..42), H2 2017 125

Products under Development by Companies, H2 2017 (Contd..43), H2 2017 126

Products under Development by Companies, H2 2017 (Contd..44), H2 2017 127

Products under Development by Companies, H2 2017 (Contd..45), H2 2017 128

Products under Development by Companies, H2 2017 (Contd..46), H2 2017 129

Products under Development by Companies, H2 2017 (Contd..47), H2 2017 130

Products under Development by Companies, H2 2017 (Contd..48), H2 2017 131

Products under Development by Companies, H2 2017 (Contd..49), H2 2017 132

Products under Development by Companies, H2 2017 (Contd..50), H2 2017 133

Products under Development by Companies, H2 2017 (Contd..51), H2 2017 134

Products under Development by Companies, H2 2017 (Contd..52), H2 2017 135

Products under Development by Companies, H2 2017 (Contd..53), H2 2017 136

Products under Development by Universities/Institutes, H2 2017 137

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 139

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 140

Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 142

Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017 143

Number of Products by Stage and Target, H2 2017 145

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 146

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 147

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 148

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 149

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 150

Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 151

Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 152

Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017 153

Number of Products by Stage and Target, H2 2017 (Contd..9), H2 2017 154

Number of Products by Stage and Mechanism of Action, H2 2017 156

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 157

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 158

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 159

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 160

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 161

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 162

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 163

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017 164

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..9), H2 2017 165

Number of Products by Stage and Route of Administration, H2 2017 167

Number of Products by Stage and Molecule Type, H2 2017 169

Non-Hodgkin Lymphoma – Pipeline by 3SBio Inc, H2 2017 170

Non-Hodgkin Lymphoma – Pipeline by 4SC AG, H2 2017 170

Non-Hodgkin Lymphoma – Pipeline by AB Science SA, H2 2017 171

Non-Hodgkin Lymphoma – Pipeline by AbbVie Inc, H2 2017 172

Non-Hodgkin Lymphoma – Pipeline by ACEA Biosciences Inc, H2 2017 173

Non-Hodgkin Lymphoma – Pipeline by Actinium Pharmaceuticals Inc, H2 2017 173

Non-Hodgkin Lymphoma – Pipeline by ADC Therapeutics Sarl, H2 2017 174

Non-Hodgkin Lymphoma – Pipeline by Affimed GmbH, H2 2017 174

Non-Hodgkin Lymphoma – Pipeline by Affitech A/S, H2 2017 175

Non-Hodgkin Lymphoma – Pipeline by Aileron Therapeutics Inc, H2 2017 175

Non-Hodgkin Lymphoma – Pipeline by Allinky Biopharma, H2 2017 175

Non-Hodgkin Lymphoma – Pipeline by Altor BioScience Corp, H2 2017 176

Non-Hodgkin Lymphoma – Pipeline by Amgen Inc, H2 2017 177

Non-Hodgkin Lymphoma – Pipeline by Angimmune LLC, H2 2017 177

Non-Hodgkin Lymphoma – Pipeline by arGEN-X BV, H2 2017 178

Non-Hodgkin Lymphoma – Pipeline by Ariad Pharmaceuticals Inc, H2 2017 178

Non-Hodgkin Lymphoma – Pipeline by Arno Therapeutics Inc, H2 2017 179

Non-Hodgkin Lymphoma – Pipeline by ArQule Inc, H2 2017 179

Non-Hodgkin Lymphoma – Pipeline by Arrien Pharmaceuticals LLC, H2 2017 180

Non-Hodgkin Lymphoma – Pipeline by Arven Ilac, H2 2017 180

Non-Hodgkin Lymphoma – Pipeline by Asana BioSciences LLC, H2 2017 180

Non-Hodgkin Lymphoma – Pipeline by Astellas Pharma Inc, H2 2017 181

Non-Hodgkin Lymphoma – Pipeline by Astex Pharmaceuticals Inc, H2 2017 181

Non-Hodgkin Lymphoma – Pipeline by AstraZeneca Plc, H2 2017 182

Non-Hodgkin Lymphoma – Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 183

Non-Hodgkin Lymphoma – Pipeline by Autolus Ltd, H2 2017 183

Non-Hodgkin Lymphoma – Pipeline by Bantam Pharmaceutical LLC, H2 2017 184

Non-Hodgkin Lymphoma – Pipeline by Bayer AG, H2 2017 185

Non-Hodgkin Lymphoma – Pipeline by BeiGene Ltd, H2 2017 186

Non-Hodgkin Lymphoma – Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 186

Non-Hodgkin Lymphoma – Pipeline by Bio-Path Holdings Inc, H2 2017 187

Non-Hodgkin Lymphoma – Pipeline by BioAtla LLC, H2 2017 187

Non-Hodgkin Lymphoma – Pipeline by Biocon Ltd, H2 2017 188

Non-Hodgkin Lymphoma – Pipeline by BioInvent International AB, H2 2017 188

Non-Hodgkin Lymphoma – Pipeline by BioLineRx Ltd, H2 2017 189

Non-Hodgkin Lymphoma – Pipeline by Bionovis SA, H2 2017 189

Non-Hodgkin Lymphoma – Pipeline by BioSight Ltd, H2 2017 190

Non-Hodgkin Lymphoma – Pipeline by Biothera Pharmaceutical Inc, H2 2017 190

Non-Hodgkin Lymphoma – Pipeline by Boehringer Ingelheim GmbH, H2 2017 191

Non-Hodgkin Lymphoma – Pipeline by Boston Biomedical Inc, H2 2017 191

Non-Hodgkin Lymphoma – Pipeline by Bristol-Myers Squibb Co, H2 2017 192

Non-Hodgkin Lymphoma – Pipeline by Calithera Biosciences Inc, H2 2017 192

Non-Hodgkin Lymphoma – Pipeline by Cascadian Therapeutics Inc, H2 2017 193

Non-Hodgkin Lymphoma – Pipeline by Celgene Corp, H2 2017 194

Non-Hodgkin Lymphoma – Pipeline by Cell Medica Ltd, H2 2017 195

Non-Hodgkin Lymphoma – Pipeline by Cell Source Inc, H2 2017 195

Non-Hodgkin Lymphoma – Pipeline by Cell>Point LLC, H2 2017 196

Non-Hodgkin Lymphoma – Pipeline by Celldex Therapeutics Inc, H2 2017 197

Non-Hodgkin Lymphoma – Pipeline by Cellectar Biosciences Inc, H2 2017 197

Non-Hodgkin Lymphoma – Pipeline by Cellectis SA, H2 2017 198

Non-Hodgkin Lymphoma – Pipeline by Celleron Therapeutics Ltd, H2 2017 198

Non-Hodgkin Lymphoma – Pipeline by Celltrion Inc, H2 2017 199

Non-Hodgkin Lymphoma – Pipeline by Cellular Biomedicine Group Inc, H2 2017 200

Non-Hodgkin Lymphoma – Pipeline by Celon Pharma SA, H2 2017 200

Non-Hodgkin Lymphoma – Pipeline by Centrose LLC, H2 2017 201

Non-Hodgkin Lymphoma – Pipeline by Cerenis Therapeutics Holding SA, H2 2017 201

Non-Hodgkin Lymphoma – Pipeline by CerRx Inc, H2 2017 201

Non-Hodgkin Lymphoma – Pipeline by Chipscreen Biosciences Ltd, H2 2017 202

Non-Hodgkin Lymphoma – Pipeline by Clevexel Pharma SAS, H2 2017 202

Non-Hodgkin Lymphoma – Pipeline by Coherus BioSciences Inc, H2 2017 203

Non-Hodgkin Lymphoma – Pipeline by CrystalGenomics Inc, H2 2017 203

Non-Hodgkin Lymphoma – Pipeline by CSPC Pharmaceutical Group Limited, H2 2017 204

Non-Hodgkin Lymphoma – Pipeline by CTI BioPharma Corp, H2 2017 205

Non-Hodgkin Lymphoma – Pipeline by Curis Inc, H2 2017 205

Non-Hodgkin Lymphoma – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 206

Non-Hodgkin Lymphoma – Pipeline by CytomX Therapeutics Inc, H2 2017 206

Non-Hodgkin Lymphoma – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 207

Non-Hodgkin Lymphoma – Pipeline by Debiopharm International SA, H2 2017 207

Non-Hodgkin Lymphoma – Pipeline by Denovo Biopharma LLC, H2 2017 208

Non-Hodgkin Lymphoma – Pipeline by Dynavax Technologies Corp, H2 2017 208

Non-Hodgkin Lymphoma – Pipeline by eFFECTOR Therapeutics Inc, H2 2017 209

Non-Hodgkin Lymphoma – Pipeline by Eisai Co Ltd, H2 2017 209

Non-Hodgkin Lymphoma – Pipeline by Eli Lilly and Co, H2 2017 210

Non-Hodgkin Lymphoma – Pipeline by Epizyme Inc, H2 2017 210

Non-Hodgkin Lymphoma – Pipeline by Erytech Pharma SA, H2 2017 211

Non-Hodgkin Lymphoma – Pipeline by Evotec AG, H2 2017 211

Non-Hodgkin Lymphoma – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 212

Non-Hodgkin Lymphoma – Pipeline by Forma Therapeutics Inc, H2 2017 213

Non-Hodgkin Lymphoma – Pipeline by Formula Pharmaceuticals Inc, H2 2017 213

Non-Hodgkin Lymphoma – Pipeline by Forty Seven Inc, H2 2017 214

Non-Hodgkin Lymphoma – Pipeline by Galderma SA, H2 2017 214

Non-Hodgkin Lymphoma – Pipeline by Genentech Inc, H2 2017 215

Non-Hodgkin Lymphoma – Pipeline by Genor BioPharma Co Ltd, H2 2017 215

Non-Hodgkin Lymphoma – Pipeline by Genosco Inc, H2 2017 216

Non-Hodgkin Lymphoma – Pipeline by Gilead Sciences Inc, H2 2017 217

Non-Hodgkin Lymphoma – Pipeline by GlaxoSmithKline Plc, H2 2017 218

Non-Hodgkin Lymphoma – Pipeline by Grupo Ferrer Internacional SA, H2 2017 218

Non-Hodgkin Lymphoma – Pipeline by GT Biopharma Inc, H2 2017 218

Non-Hodgkin Lymphoma – Pipeline by H3 Biomedicine Inc, H2 2017 219

Non-Hodgkin Lymphoma – Pipeline by Heidelberg Pharma GmbH, H2 2017 219

Non-Hodgkin Lymphoma – Pipeline by Humorigin Biotechnology Corp, H2 2017 219

Non-Hodgkin Lymphoma – Pipeline by Hutchison MediPharma Ltd, H2 2017 220

Non-Hodgkin Lymphoma – Pipeline by iDD biotech SAS, H2 2017 220

Non-Hodgkin Lymphoma – Pipeline by IGF Oncology LLC, H2 2017 221

Non-Hodgkin Lymphoma – Pipeline by Ignyta Inc, H2 2017 221

Non-Hodgkin Lymphoma – Pipeline by Immune Design Corp, H2 2017 222

Non-Hodgkin Lymphoma – Pipeline by ImmunGene Inc, H2 2017 222

Non-Hodgkin Lymphoma – Pipeline by ImmunoGen Inc, H2 2017 223

Non-Hodgkin Lymphoma – Pipeline by Immunomedics Inc, H2 2017 224

Non-Hodgkin Lymphoma – Pipeline by Immunovaccine Inc, H2 2017 224

Non-Hodgkin Lymphoma – Pipeline by Incyte Corp, H2 2017 226

Non-Hodgkin Lymphoma – Pipeline by Inflection Biosciences Ltd, H2 2017 227

Non-Hodgkin Lymphoma – Pipeline by Innate Pharma SA, H2 2017 227

Non-Hodgkin Lymphoma – Pipeline by Innovent Biologics Inc, H2 2017 227

Non-Hodgkin Lymphoma – Pipeline by Japan Tobacco Inc, H2 2017 228

Non-Hodgkin Lymphoma – Pipeline by JHL Biotech Inc, H2 2017 228

Non-Hodgkin Lymphoma – Pipeline by Johnson & Johnson, H2 2017 229

Non-Hodgkin Lymphoma – Pipeline by Juno Therapeutics Inc, H2 2017 230

Non-Hodgkin Lymphoma – Pipeline by K-Stemcell Co Ltd, H2 2017 230

Non-Hodgkin Lymphoma – Pipeline by Kainos Medicine Inc, H2 2017 231

Non-Hodgkin Lymphoma – Pipeline by Karyopharm Therapeutics Inc, H2 2017 231

Non-Hodgkin Lymphoma – Pipeline by Kite Pharma Inc, H2 2017 232

Non-Hodgkin Lymphoma – Pipeline by Klyss Biotech Inc, H2 2017 232

Non-Hodgkin Lymphoma – Pipeline by Komipharm International Co Ltd, H2 2017 233

Non-Hodgkin Lymphoma – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 234

Non-Hodgkin Lymphoma – Pipeline by Leadiant Biosciences Inc, H2 2017 234

Non-Hodgkin Lymphoma – Pipeline by Les Laboratoires Servier SAS, H2 2017 234

Non-Hodgkin Lymphoma – Pipeline by LFB SA, H2 2017 235

Non-Hodgkin Lymphoma – Pipeline by Loxo Oncology Inc, H2 2017 235

Non-Hodgkin Lymphoma – Pipeline by LSK BioPartners Inc, H2 2017 236

Non-Hodgkin Lymphoma – Pipeline by Mabion SA, H2 2017 236

Non-Hodgkin Lymphoma – Pipeline by MacroGenics Inc, H2 2017 237

Non-Hodgkin Lymphoma – Pipeline by Meabco AS, H2 2017 237

Non-Hodgkin Lymphoma – Pipeline by MedImmune LLC, H2 2017 238

Non-Hodgkin Lymphoma – Pipeline by Medivir AB, H2 2017 238

Non-Hodgkin Lymphoma – Pipeline by MEI Pharma Inc, H2 2017 239

Non-Hodgkin Lymphoma – Pipeline by MENTRIK Biotech LLC, H2 2017 239

Non-Hodgkin Lymphoma – Pipeline by Merck & Co Inc, H2 2017 240

Non-Hodgkin Lymphoma – Pipeline by Merck KGaA, H2 2017 241

Non-Hodgkin Lymphoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 242

Non-Hodgkin Lymphoma – Pipeline by Miltenyi Biotec GmbH, H2 2017 243

Non-Hodgkin Lymphoma – Pipeline by Miragen Therapeutics Inc, H2 2017 243

Non-Hodgkin Lymphoma – Pipeline by Mirati Therapeutics Inc, H2 2017 244

Non-Hodgkin Lymphoma – Pipeline by Molecular Templates Inc, H2 2017 244

Non-Hodgkin Lymphoma – Pipeline by Moleculin Biotech Inc, H2 2017 244

Non-Hodgkin Lymphoma – Pipeline by Morphogenesis Inc, H2 2017 245

Non-Hodgkin Lymphoma – Pipeline by MorphoSys AG, H2 2017 245

Non-Hodgkin Lymphoma – Pipeline by NantKwest Inc, H2 2017 246

Non-Hodgkin Lymphoma – Pipeline by NBE-Therapeutics AG, H2 2017 246

Non-Hodgkin Lymphoma – Pipeline by Neumedicines Inc, H2 2017 247

Non-Hodgkin Lymphoma – Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2017 247

Non-Hodgkin Lymphoma – Pipeline by Nordic Nanovector ASA, H2 2017 248

Non-Hodgkin Lymphoma – Pipeline by NovaLead Pharma Pvt Ltd, H2 2017 248

Non-Hodgkin Lymphoma – Pipeline by Novartis AG, H2 2017 249

Non-Hodgkin Lymphoma – Pipeline by NovImmune SA, H2 2017 250

Non-Hodgkin Lymphoma – Pipeline by Oncobiologics Inc, H2 2017 250

Non-Hodgkin Lymphoma – Pipeline by Onconova Therapeutics Inc, H2 2017 251

Non-Hodgkin Lymphoma – Pipeline by Oncopeptides AB, H2 2017 251

Non-Hodgkin Lymphoma – Pipeline by OncoSec Medical Inc, H2 2017 251

Non-Hodgkin Lymphoma – Pipeline by Oncovir Inc, H2 2017 252

Non-Hodgkin Lymphoma – Pipeline by Oncternal Therapeutics Inc, H2 2017 252

Non-Hodgkin Lymphoma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 253

Non-Hodgkin Lymphoma – Pipeline by Onxeo SA, H2 2017 254

Non-Hodgkin Lymphoma – Pipeline by Oxford BioTherapeutics Ltd, H2 2017 254

Non-Hodgkin Lymphoma – Pipeline by Patrys Ltd, H2 2017 254

Non-Hodgkin Lymphoma – Pipeline by Pfizer Inc, H2 2017 255

Non-Hodgkin Lymphoma – Pipeline by Pharma Mar SA, H2 2017 256

Non-Hodgkin Lymphoma – Pipeline by Philogen SpA, H2 2017 256

Non-Hodgkin Lymphoma – Pipeline by PIQUR Therapeutics AG, H2 2017 256

Non-Hodgkin Lymphoma – Pipeline by Plexxikon Inc, H2 2017 257

Non-Hodgkin Lymphoma – Pipeline by Polaris Pharmaceuticals Inc, H2 2017 257

Non-Hodgkin Lymphoma – Pipeline by Portola Pharmaceuticals Inc, H2 2017 258

Non-Hodgkin Lymphoma – Pipeline by Prescient Therapeutics Ltd, H2 2017 258

Non-Hodgkin Lymphoma – Pipeline by Rafael Pharmaceuticals Inc, H2 2017 259

Non-Hodgkin Lymphoma – Pipeline by RedHill Biopharma Ltd, H2 2017 259

Non-Hodgkin Lymphoma – Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 260

Non-Hodgkin Lymphoma – Pipeline by Respiratorius AB, H2 2017 260

Non-Hodgkin Lymphoma – Pipeline by Rhizen Pharmaceuticals SA, H2 2017 261

Non-Hodgkin Lymphoma – Pipeline by Richter Gedeon Nyrt, H2 2017 261

Non-Hodgkin Lymphoma – Pipeline by Sandoz International GmbH, H2 2017 262

Non-Hodgkin Lymphoma – Pipeline by Sanofi, H2 2017 262

Non-Hodgkin Lymphoma – Pipeline by Sareum Holdings Plc, H2 2017 263

Non-Hodgkin Lymphoma – Pipeline by Seattle Genetics Inc, H2 2017 264

Non-Hodgkin Lymphoma – Pipeline by Selvita SA, H2 2017 265

Non-Hodgkin Lymphoma – Pipeline by Senhwa Biosciences Inc, H2 2017 265

Non-Hodgkin Lymphoma – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017 266

Non-Hodgkin Lymphoma – Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2017 266

Non-Hodgkin Lymphoma – Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, H2 2017 267

Non-Hodgkin Lymphoma – Pipeline by Sierra Oncology Inc, H2 2017 267

Non-Hodgkin Lymphoma – Pipeline by Sigma-Tau SpA, H2 2017 268

Non-Hodgkin Lymphoma – Pipeline by Solasia Pharma KK, H2 2017 268

Non-Hodgkin Lymphoma – Pipeline by Soligenix Inc, H2 2017 269

Non-Hodgkin Lymphoma – Pipeline by Sorrento Therapeutics Inc, H2 2017 269

Non-Hodgkin Lymphoma – Pipeline by Spectrum Pharmaceuticals Inc, H2 2017 270

Non-Hodgkin Lymphoma – Pipeline by Stemline Therapeutics Inc, H2 2017 270

Non-Hodgkin Lymphoma – Pipeline by Sunesis Pharmaceuticals Inc, H2 2017 271

Non-Hodgkin Lymphoma – Pipeline by Supratek Pharma Inc, H2 2017 271

Non-Hodgkin Lymphoma – Pipeline by Surface Oncology Inc, H2 2017 272

Non-Hodgkin Lymphoma – Pipeline by Sutro Biopharma Inc, H2 2017 272

Non-Hodgkin Lymphoma – Pipeline by Syndax Pharmaceuticals Inc, H2 2017 273

Non-Hodgkin Lymphoma – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017 273

Non-Hodgkin Lymphoma – Pipeline by Taiwan Liposome Company Ltd, H2 2017 274

Non-Hodgkin Lymphoma – Pipeline by TC BioPharm Ltd, H2 2017 274

Non-Hodgkin Lymphoma – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 274

Non-Hodgkin Lymphoma – Pipeline by TG Therapeutics Inc, H2 2017 275

Non-Hodgkin Lymphoma – Pipeline by TRACON Pharmaceuticals Inc, H2 2017 276

Non-Hodgkin Lymphoma – Pipeline by Transgene Biotek Ltd, H2 2017 276

Non-Hodgkin Lymphoma – Pipeline by Transgene SA, H2 2017 277

Non-Hodgkin Lymphoma – Pipeline by Trillium Therapeutics Inc, H2 2017 277

Non-Hodgkin Lymphoma – Pipeline by Trovagene Inc, H2 2017 278

Non-Hodgkin Lymphoma – Pipeline by TTY Biopharm Company Ltd, H2 2017 278

Non-Hodgkin Lymphoma – Pipeline by United BioPharma Inc, H2 2017 278

Non-Hodgkin Lymphoma – Pipeline by Unum Therapeutics Inc, H2 2017 279

Non-Hodgkin Lymphoma – Pipeline by Verastem Inc, H2 2017 279

Non-Hodgkin Lymphoma – Pipeline by Vivolux AB, H2 2017 280

Non-Hodgkin Lymphoma – Pipeline by Vyriad Inc, H2 2017 280

Non-Hodgkin Lymphoma – Pipeline by Xencor Inc, H2 2017 281

Non-Hodgkin Lymphoma – Pipeline by Xenetic Biosciences Inc, H2 2017 281

Non-Hodgkin Lymphoma – Pipeline by ZIOPHARM Oncology Inc, H2 2017 282

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 1949

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..1), H2 2017 1950

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..2), H2 2017 1951

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..3), H2 2017 1952

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..4), H2 2017 1953

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..5), H2 2017 1954

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..6), H2 2017 1956

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..7), H2 2017 1957

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..8), H2 2017 1958

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..9), H2 2017 1959

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..10), H2 2017 1960

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..11), H2 2017 1961

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..12), H2 2017 1962

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..13), H2 2017 1963

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..14), H2 2017 1964

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..15), H2 2017 1965

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..16), H2 2017 1966

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..17), H2 2017 1967

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..18), H2 2017 1968

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..19), H2 2017 1969

Non-Hodgkin Lymphoma – Dormant Projects, H2 2017 (Contd..20), H2 2017 1970

Non-Hodgkin Lymphoma – Discontinued Products, H2 2017 1971

Non-Hodgkin Lymphoma – Discontinued Products, H2 2017 (Contd..1), H2 2017 1972

Non-Hodgkin Lymphoma – Discontinued Products, H2 2017 (Contd..2), H2 2017 1973

Non-Hodgkin Lymphoma – Discontinued Products, H2 2017 (Contd..3), H2 2017 1974

Non-Hodgkin Lymphoma – Discontinued Products, H2 2017 (Contd..4), H2 2017 1975

Non-Hodgkin Lymphoma – Discontinued Products, H2 2017 (Contd..5), H2 2017 1976

Non-Hodgkin Lymphoma – Discontinued Products, H2 2017 (Contd..6), H2 2017 1977

Non-Hodgkin Lymphoma – Discontinued Products, H2 2017 (Contd..7), H2 2017 1978

List of Figures

List of Figures

Number of Products under Development for Non-Hodgkin Lymphoma, H2 2017 63

Number of Products under Development by Companies, H2 2017 64

Number of Products under Development by Universities/Institutes, H2 2017 79

Number of Products by Top 10 Targets, H2 2017 144

Number of Products by Stage and Top 10 Targets, H2 2017 144

Number of Products by Top 10 Mechanism of Actions, H2 2017 155

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 155

Number of Products by Routes of Administration, H2 2017 166

Number of Products by Stage and Routes of Administration, H2 2017 166

Number of Products by Top 10 Molecule Types, H2 2017 168

Number of Products by Stage and Top 10 Molecule Types, H2 2017 168

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports